Paired diagnostic and pharmacodynamic analysis of rare non-small cell lung cancer cells enabled by the VerIFAST platform

摘要: Lung cancer is the leading cause of cancer-related deaths in United States and worldwide. This has led to major research initiatives focusing on improving early diagnosis rate, as well development pharmacodynamic biomarkers. However, broad clinical integration these approaches limited due invasive nature lung biopsies, needle aspirates resections. Recently, an advance for sampling suspicious nodules collect mini-bronchoalveolar lavage (mBAL) samples was shown be diagnostically relevant but by standard cytology techniques low sensitivity specificity. In addition, a second non-invasive method that holds great promise collection circulating tumor cells, rare population cells have shed into peripheral circulation from primary or metastatic sites, blood. Here, we utilize recently published platform, VerIFAST, capture proteomic analysis isolate interest patients using both mBAL blood samples. The VerIFAST platform leverages surface tension at microscale pin aqueous oil fluids adjacent chambers create virtual filter between two fluids. this manuscript, further enhanced include pinning, which allowed on-device tumbling, eliminating laborious time consuming step could result increased sample loss. Finally, developed base assays used histopathologic diagnostic cells. Specifically, examined thyroid transcription factor-1 (TTF-1) signal intensity, loss associated with more aggressive disease, epidermal growth factor receptor (EGFR) high value therapeutic target cancer.